Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
European Respiratory Journal · 2024
DOI: 10.1183/13993003.01392-2023 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Michael Dooney und 1 weiteren Autor:innen. Beteiligte Einrichtung: Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool Adult Cystic Fibrosis Service, Blackpool Victoria Hospital, Blackpool, UK michaeldooney@…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Indoles, Aminophenols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
We have read with great interest the work of Burgel et al. [1] and applaud them for their innovative use of elexacaftor/tezacaftor/ivacaftor (ETI) in combination with ivacaftor (IVA) in people with significant cystic fibrosis (CF) respiratory disease who were carriers of cystic fibrosis transmembrane conductance regulator (CFTR) variants that did not meet eligibility criteria for funded treatment. The observed response rate of 54% is impressive and regulatory bodies should take note of such a result, especially considering that a profound treatment effect was observed in those who responded. Elexacaftor/tezacaftor/ivacaftor is effective in more people with cystic fibrosis than initially thought with targeted use
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool Adult Cystic Fibrosis Service, Blackpool Victoria Hospital, Blackpool, UK michaeldooney@nhs.net.
- Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool Adult Cystic Fibrosis Service, Blackpool Victoria Hospital, Blackpool, UK.
Zitieren
APA
Dooney, M., & Saba, T. (2024). Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. European Respiratory Journal. https://doi.org/10.1183/13993003.01392-2023
Vancouver
Dooney M, Saba T. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. European Respiratory Journal. 2024. doi:10.1183/13993003.01392-2023
BibTeX
@article{Dooney2024,
author = {Dooney, Michael and Saba, Tarek},
title = {Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme},
journal = {European Respiratory Journal},
year = {2024},
doi = {10.1183/13993003.01392-2023}
}
EUVIMED